ALECENSA is a treatment for metastatic a ALK+ non-small cell lung cancer (NSCLC) ALECENSA is an oral medicine that may help you live longer without the disease getting worse (compared …

Jul 2, 2024 · Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of non-small cell lung cancer (NSCLC) in adults that have been caused by an abnormal …

May 8, 2024 · FDA has approved alectinib (Alecensa) as an adjuvant therapy for people with non-small cell lung cancer (NSCLC) who have ALK-positive tumors.

Alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Alecensa (alectinib) is a medicine used for treating certain lung cancers. Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.

On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma …

Sep 4, 2019 · ALECENSA (alectinib) Fact Sheet ALECENSA® (alectinib) Fact Sheet ALECENSA is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase …

Who is ALECENSA for? ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) …

Apr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and …

Aug 2, 2024 · Alecensa is also used as an adjuvant treatment in adult patients following tumor resection of (ALK)-positive non-small cell lung cancer (NSCLC) when tumors ≥ 4 cm or node …